Aristides Capital’s iShares Biotechnology ETF IBB Stock Holding History

Aristides Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28,467	Closed	-$3.6M	–	265
2025 Q2	$3.6M	Buy	+28,467	New	+$3.49M	0.72%	29
2024 Q3	–	Sell	-66,880	Closed	-$9.18M	–	273
2024 Q2	$9.18M	Buy	+66,880	New	+$8.93M	2.59%	5
2023 Q3	–	Sell	-63,773	Closed	-$8.1M	–	195
2023 Q2	$8.1M	Buy	+63,773	New	+$8.28M	3.29%	4
2022 Q3	–	Sell	-20,815	Closed	-$2.45M	–	166
2022 Q2	$2.45M	Buy	20,815 +7,515	+57%	+$892K	1.68%	15
2022 Q1	$1.73M	Sell	13,300 -5,500	-29%	-$716K	1.06%	19
2021 Q4	$2.87M	Buy	18,800 +7,000	+59%	+$1.08M	1.31%	16
2021 Q3	$1.91M	Sell	11,800 -36,750	-76%	-$6.18M	0.7%	29
2021 Q2	$7.95M	Buy	48,550 +44,150	+1,003%	+$6.8M	1.87%	7
2021 Q1	$662K	Buy	+4,400	New	+$699K	0.27%	67
2020 Q4	–	Sell	-6,020	Closed	-$815K	–	175
2020 Q3	$815K	Sell	6,020 -36,356	-86%	-$4.93M	0.57%	34
2020 Q2	$5.79M	Buy	+42,376	New	+$5.4M	4.37%	5

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Aristides Capital's IBB Position: Q3 2025 in Review

Aristides Capital sold out of iShares Biotechnology ETF (IBB) in Q3 2025, closing a stake of 28,467 shares — an estimated $3.6M sold.

Aristides Capital first reported a position in IBB in Q2 2020 and held it in 11 quarters. The position peaked at $9.18M in Q2 2024. 803 funds tracked by Wall St. Rank hold IBB as of Q3 2025.

Aristides Capital reported no remaining iShares Biotechnology ETF position as of Q3 2025 after selling out during the quarter.
Aristides Capital sold 28,467 iShares Biotechnology ETF shares in Q3 2025, an estimated $3.6M.
Aristides Capital first reported a position in iShares Biotechnology ETF in Q2 2020 and held it in 11 quarters.
Aristides Capital's iShares Biotechnology ETF position peaked at $9.18M in Q2 2024.
803 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2025.

Based on Aristides Capital's 13F filing for Q3 2025, filed 13 Nov 2025.